Abstract 1540P
Background
Neoadjuvant chemoradiotherapy (nCRT) is a standard treatment for resectable locally advanced oesophageal squamous cell carcinoma (ESCC); however, its effectiveness is curtailed by recurrence and distant metastasis. Developing novel therapies, such as combined checkpoint inhibitors, is crucial for improving patient survival. Tislelizumab, an anti-PD-1 monoclonal antibody, has shown promise in various malignancies. This is the first phase II study to assess the efficacy and safety of Tislelizumab combined with nCRT for resectable locally advanced ESCC.
Methods
All subjects underwent nCRT with a 40 Gy total radiation dose given daily for 5 days/week. Paclitaxel albumin (taxanes) with cisplatin/carboplatin were given on days 1 and 22, while Tislelizumab was administered twice on days 8 and 29 concurrently with radiation therapy. Finally, surgery was performed at 6-8 weeks post-treatment.
Results
By April 2023, 26 patients were enrolled in the study, with 21 undergoing surgical resection at a 100% R0 resection rate. Patients who received Tislelizumab combined with nCRT achieved a 100% objective remission rate, with 9 (42.8%) patients had complete response rate and 14 (66.6%) patients achieved major pathologic response, no surgical delay, among 6 patients continue to receive postoperative adjuvant therapy. Common side-effects included leukopenia, thrombocytopenia, neutropenia, anemia, anastomotic leakage, and rash. Most adverse events were grades 1/2, and grades 3/4 adverse events include four cases of grade 3 leukopenia, and one case of grade 3 neutropenia. Regrettably, 2 patients have passed away due to the novel coronavirus. The analysis of survival was immature, and patients are still being followed up.
Conclusions
Tislelizumab in combination with nCRT is a safe and effective treatment strategy for resectable locally advanced ESCC. The high complete response rate and favorable safety profile observed in this study warrant further investigation in larger, randomized controlled trials to confirm the benefit of Tislelizumab in improving treatment outcomes for patients with locally advanced ESCC.
Clinical trial identification
CTR2100051599.
Editorial acknowledgement
The drug was kindly provided by Beigene and Kelun.
Legal entity responsible for the study
The authors.
Funding
Clinical Research Incubation Project, West China Hospital, Sichuan University; Science and Technology Department of Sichuan Province; Beijing Medical Award Foundation; the 1·3·5 project for disciplines of excellence; National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21